5 registrations that name tart cherry as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 5 registrations
Status
Phase
4US sites across 2 states
1
2 to 4
5 to 19
20 or more
All 5 registrations
RecruitingNCT06123286
Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms
Early phase 1
Philip Chang
About 30 people
Started Sep 12, 2025
In plain words An early phase 1 study of tart cherry in female participants 18 and older, run by Philip Chang. It plans to enroll about 30 people at 2 US sites.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 and older. Conditions: Breast Cancer; Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS); Joint Pain.
Breast cancer diagnosis (Stage I-III) with any hormonal status.
Females aged ≥ 18 years.
Currently receiving AI therapy.
BMI ≥ 27.
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Tart Cherry; Omega 3 FA (Fish Oil)
Registered summary
Both Tart Cherry and Omega 3 FAs have better side effect profiles compared to other commonly used medications for AIMSS, such as nonsteroidal anti-inflammatories, steroids, and serotonin norepinephrine reuptake inhibitors. Additionally, in our clinics we often find that patients tend to be more receptive to taking a supplement as opposed to an additional medication. Further, both Tart Cherry concentrate and fish oil have beneficial properties for helping with joint stiffness in general, in addition to other health issues like insomnia. The full summary is on the listing.
Where, as registered
2 US sites in 1 state.
RecruitingNCT06268665
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
Phase 2
University of California, Davis
About 86 people
Started Aug 15, 2024
In plain words A Phase 2 study of tart cherry in people 18 and older, run by University of California, Davis. It plans to enroll about 86 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Breast Cancer; Breast Cancer Stage I; Breast Cancer Stage II; Breast Cancer Stage III; Breast Cancer Stage IV; Invasive Breast Cancer; Ovarian Cancer; Ovarian Cancer Stage 1; Ovarian Cancer Stage II; Ovarian Cancer Stage III; Ovarian Cancer Stage IV; Ovarian Cancer Stage IA; Ovarian Cancer Stage IB; Ovarian Cancer Stage IC; Ovarian Cancer Stage 2; Ovarian Cancer Stage 3; Ovarian Cancer Stage IIIb; Ovarian Cancer Stage IIIC; Breast Cancer Stage IIIA; Breast Cancer Invasive; Breast Cancer, Stage IA; Breast Cancer, Stage IB; Breast Cancer Stage IIA; Breast Cancer Stage IIB; Breast Cancer Stage IIIB; Breast Cancer Stage IIIc; Cancer, Breast; Tumors, Breast; Mammary Cancer; Mammary Carcinoma; Breast Carcinoma; Breast Neoplasm; Malignant Breast Neoplasm; Malignant Tumor of Breast; Cancer of Ovary; Ovary Cancer; Ovary Neoplasm.
Histologically confirmed invasive breast or ovarian cancer (Stage I, II, III, or IV) as per AJCC 8th Edition, 2018 Staging Criteria.
Must be planning to receive paclitaxel weekly for 12 weeks (12 weeks total) as part of neoadjuvant, adjuvant, or metastatic cancer treatment.
Concurrent biologic therapy (e.g., trastuzumab and pertuzumab) is allowed.
Currently receiving hormone therapy, bisphosphonates, denosumab or LHRH-agonists is allowed.
15 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Tart Cherry Juice
Registered summary
This is a single institution phase II randomized study evaluating the potential benefits of a supplement, tart cherry juice at high- versus low-doses, to prevent taxane induced peripheral neuropathy in breast and ovarian cancer patients undergoing paclitaxel chemotherapy. Eligible participants enrolled onto the study will be block randomized in a 1:1 allocation to either the tart cherry juice high-dose group (Arm 1) or the tart cherry juice low-dose group (Arm 2).
Where, as registered
1 US site in 1 state.
RecruitingNCT07063173
Bioavailability of Ration Items Containing Tart Cherry Extract
No phase
United States Army Research Institute of Environmental Medicine
About 15 people
Started Jun 14, 2024
In plain words A study of tart cherry in people 17 to 39, run by United States Army Research Institute of Environmental Medicine. It plans to enroll about 15 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 17 to 39; healthy volunteers accepted. Conditions: Bioavailability.
Active duty military personnel and civilians will be invited to participate in the study if they:
Are between the ages of 18 (or 17 for military personnel) and 39.
Are willing to participate in all study procedures and comply with all study instruction.
In good health as determined by OMSO (Office of Medical Support and Oversight).
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Fruit Bar; Powdered Drink; Commercially available 100% tart cherry juice; Placebo beverage
Registered summary
To determine how consuming food items containing shelf-stored tart cherry impacts your body's ability to absorb and use the compounds within tart cherry.
Where, as registered
1 US site in 1 state.
RecruitingNCT07613138
Tart Cherry Citrate Effervescent Tablet for Urate-Lowering Therapy in Participants With Asymptomatic Hyperuricemia
No phase
Beijing Zhecheng Biotechnology Co., Ltd.
About 196 people
Started Jun 4, 2026
In plain words A study of tart cherry in people 18 to 65, run by Beijing Zhecheng Biotechnology Co., Ltd.. It plans to enroll about 196 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Hyperuricemia With or Without Gout.
Aged 18 to 65 years, regardless of sex;
Meet the diagnostic criteria for primary hyperuricemia, with serum urate levels between 420 μmol/L and 540 μmol/L (for those without comorbidities) or between 420 μmol/L and 480 μmol/L (for those with at least one of the following…
Participants with asymptomatic hyperuricemia who have not previously received urate-lowering therapy and have no history of acute gout flares;
Voluntarily participate in the study and provide written informed consent.
The exclusion criteria are on the listing.
What it tests, as registered
tart cherry citrate effervescent table; Placebo Control Group
Registered summary
The goal of this clinical trial is to learn whether tart cherry citrate effervescent tablets can lower uric acid levels in people with asymptomatic hyperuricemia (high uric acid levels without gout symptoms). The main question it aims to answer is: Does taking tart cherry citrate effervescent tablets lower uric acid levels more effectively than taking a placebo (inactive) tablet, when both groups also receive lifestyle guidance? Researchers will compare two groups of participants. Both groups will receive lifestyle guidance (advice on diet and exercise). The full summary is on the listing.
Where, as registered
No US site; China (1).
Not yet recruitingNCT06901986
Health Benefits of Tart Cherry in Crohn's Disease
No phase
University of Central Lancashire
About 52 people
Starts Jan 1, 2026 (estimated)
In plain words A study of tart cherry in people 18 to 65, run by University of Central Lancashire. It plans to enroll about 52 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Crohn Disease (CD).
An established diagnosis of CDfor at least 6 months
Current mild to moderate disease activity
Age between 18 and 65 years
Stable use of medication for at least 3 months respectively.
The exclusion criteria are on the listing.
What it tests, as registered
Montmorency tart cherry; Placebo
Registered summary
Crohn's disease (CD) is a long-term inflammatory condition of the digestive tract. People with CD often experience unpredictable and debilitating symptoms, including abdominal pain, diarrhea, and fatigue. Additionally, they require long-term treatment, which is often associated with frequent negative effects, the need for surgery, and hospitalizations. As a result, individuals with CD report a lower health-related quality of life (HRQOL) compared to healthy individuals. The full summary is on the listing.